Forte Biosciences, Inc.

FBRXSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1419041

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue from Contract with Customer, Excluding Assessed Tax	—	—	—	—	—
Research and Development Expense	—	—	—	—	—
Operating Expenses	$32.5M	$13.9M	$21.5M	$46.3M	$4.1M
Operating Income (Loss)	-$32.5M	-$13.9M	-$21.5M	-$46.3M	-$4.1M
Nonoperating Income (Expense)	—	—	—	—	—
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$31.5M	—	—	—	—
Income Tax Expense (Benefit)	—	—	—	—	—
Net Income (Loss) Attributable to Parent

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Assets	$39.0M	$42.0M	$43.3M	$61.2M	$7.7M
Assets, Current	$38.3M	$41.5M	$42.5M	$59.9M	$7.5M
Cash and Cash Equivalents, at Carrying Value	$37.1M	$41.1M	$42.0M	$58.8M	$6.9M
Liabilities	—	—	—	—	—
Liabilities, Current	$3.7M	$3.2M	$1.8M	$2.3M	$1.9M
Long-term Debt, Excluding Current Maturities	—	—	—	—	—
Accounts Payable, Current	$1.4M	$1.2M	$946.0K	$1.2M	$1.6M

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Net Cash Provided by (Used in) Operating Activities	-$28.7M	-$8.2M	-$16.7M	-$18.4M	-$2.8M
Net Cash Provided by (Used in) Investing Activities	$47.0K	$47.0K	—	$3.6M	-$162.0K
Net Cash Provided by (Used in) Financing Activities	$24.7M	$7.2M	-$44.0K	$66.7M	$4.9M
Payments to Acquire Property, Plant, and Equipment	$88.0K	$88.0K	—	—	$162.0K

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)